Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Li, Nanxin; Hao, Yanbin; Xie, Jipan; Lin, Psang Dain; Zhou, Zhou; Zhong, Yichen; Signorovitch, James; Wu, Eric Q.

doi:10.1185/03007995.2015.1062358

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82.7% patients had visceral metastasis, 60% of them had more than 3 metastatic sites, and 77.3% had received chemotherapy in metastatic settings before everolimus while the corresponding percentage in BOLERO-2 was 58%, 35% and 26%, respectively. The patients’ characteristics in our study are consistent with findings from other real-world studies that oncologists tend to consider the addition of everolimus to endocrine therapy in patients with visceral metastasis, higher tumor burden, and in later lines of treatment [ 19 , 20 ]. These discrepancies highlight the gap between randomized trials and real-world treatment.…”

Section: Discussionsupporting

confidence: 89%

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

et al. 2017

View full text Add to dashboard Cite

BackgroundEverolimus combined with endocrine therapy has been proved to be effective among postmenopausal women with hormone receptor-positive human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (MBC). We aimed to evaluate the efficacy and safety of everolimus plus endocrine therapy in Chinese real-world practice for the first time, and investigate factors associated with efficacy.MethodsSeventy-five HR+/HER2- MBC patients were included in this retrospective study who received everolimus plus endocrine therapy after progression on prior endocrine therapy in Fudan University Shanghai Cancer Center (FUSCC) between June 2013 and February 2016. Main outcome measures are progression free survival (PFS), overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety profile.ResultsAfter a median follow up of 10.3 (range: 2.1-32.2) months, median PFS was 5.9 months (95%CI 4.6-7.2), and median OS was not reached. The CBR was 38.8% (95%CI, 26.8-50.8) and ORR was 9.0% (95%CI, 2.0-16.0). Most common all-grade adverse events were stomatitis (57.1%), fatigue (25.7%), infection (24.3%) and hyperglycemia (21.4%). The most common ≥3 grade adverse events were stomatitis (9.3 %) and thrombocytopenia (5.7%). No treatment-related death was documented during and one month after the drug administration.ConclusionsThe combination of everolimus and endocrine therapy proved to be effective in Chinese population. The safety profiles were similar to previous studies but incidences were lower. In conclusion, everolimus combined with endocrine therapy provides a reasonable option for Chinese HR+/HER2- metastatic breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Of all the topics we searched, we found the greatest number of studies on treatment patterns in HER2-negative and TN mBC: ten articles [29][30][31][32][33][34][35][36][37][38] and eight conference abstracts (Table 4) [39,40,41,42,43,44,45,46]. Ten of these were retrospective chart reviews [29,30,[32][33][34]37,38,41,44,45], two were physician surveys [31,46] and six were analyses of secondary databases (e.g., Surveillance, Epidemiology and End Results [SEER]-Medicare database, commercial claims) [35,36,39,40,42,43].…”

Section: Overview Of Treatment Patterns Studiesmentioning

confidence: 99%

“…Ten of these were retrospective chart reviews [29,30,[32][33][34]37,38,41,44,45], two were physician surveys [31,46] and six were analyses of secondary databases (e.g., Surveillance, Epidemiology and End Results [SEER]-Medicare database, commercial claims) [35,36,39,40,42,43]. These studies examined a variety of therapeutic options, including endocrine therapy, chemotherapy and surgery.…”

Section: Overview Of Treatment Patterns Studiesmentioning

confidence: 99%

“…The median survival from diagnosis of brain metastasis in mTNBC was 5 months. Li et al [30] conducted a retrospective chart review of 699 postmenopausal HRpositive/HER2-negative mBC women who received everolimus, endocrine therapy or chemotherapy after a NSAI failure, with data from community-based oncology practices across the USA. The study aim was to examine the factors associated with everolimus use in these patients in the real-world setting.…”

Section: Overview Of Treatment Patterns Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review

Parisi¹,

Pelletier²,

Cherepanov

et al. 2018

J. Comp. Eff. Res.

View full text Add to dashboard Cite

Aim:With the aggregation of real-world data in healthcare, opportunities for outcomes research are growing. In this study, we summarize published literature examining comparative effectiveness research (CER), treatment patterns, quality of life (QoL) and costs in HER2-negative and triple-negative (TN) metastatic breast cancer (mBC). Methods: PubMed (2010-January 2016) and four conferences (2013-January 2016) were searched using MeSH/keywords, including mBC, QoL, morbidity and therapeutics. Studies relating to CER, treatment patterns, QoL, costs or treatment appropriateness in US patients with HER2-negative/TN mBC were included in the review. Results: Of 1782 identified records, 33 studies met full inclusion criteria: seven related to CER, 18 to treatment patterns, one to treatment appropriateness/navigation, two to QoL and five to costs. Studies varied in objectives, designs and outcomes. Study designs included retrospective chart reviews (52%), retrospective secondary database analyses (27%), economic models (12%), physician surveys (6%) and patient surveys (3%). 25 studies reported results on HER2-negative mBC, six on TN mBC and two on both subtypes. The most common end points examined were treatment patterns, overall survival and progression-free survival. Conclusion: Outcomes research in HER2-negative mBC in the USA was limited, specifically among TN patients, indicating an opportunity for further research in this high unmet need population. Endpoints and treatment options varied, thus, it is difficult to draw summary conclusions about these studies. Outcomes research examining real-world data in mBC has increased in recent years, and may continue to grow with the implementation of new policy programs. Breast cancer is the most common cancer type among women in the USA. 29% of incident cancer cases are attributable to breast cancer alone [1]. About 66% of women with breast cancer have HER2-negative and 10-17% have HER2-negative, estrogen receptor-negative (ER-negative) and progesterone receptor-negative (PR-negative) cancer, referred to as triple-negative breast cancer (TNBC) [2,3]. In 2016, an estimated 246,660 women were newly diagnosed with breast cancer, of which approximately 6% had metastatic or stage IV disease at the time of diagnosis [1,4,5]. About 30% of women initially diagnosed with early-stage breast cancer develop recurrent advanced or metastatic disease [6,7]. The 5-year survival rate with stage IV breast cancer is only 26.3% [4,5].Tumor markers in breast cancer impact prognosis, treatment and survival [8]. Prognosis has improved significantly for patients with metastatic HER2-positive breast cancer with emergence of trastuzumab and other anti-HER2 agents but has lagged for patients with advanced HER2-negative breast cancer since the emergence of effective new targeted therapies such as everolimus is only beginning [9]. Moreover, an important minority of these patients, those with triple-negative (TN) disease, has a relatively poor prognosis given the lack of targeted therapies, leaving cytoto...

show abstract

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

Guérin

Hao

Tang

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Cited by 4 publications

References 22 publications

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

Contact Info

Product

Resources

About